JPH0212932B2 - - Google Patents
Info
- Publication number
- JPH0212932B2 JPH0212932B2 JP812686A JP812686A JPH0212932B2 JP H0212932 B2 JPH0212932 B2 JP H0212932B2 JP 812686 A JP812686 A JP 812686A JP 812686 A JP812686 A JP 812686A JP H0212932 B2 JPH0212932 B2 JP H0212932B2
- Authority
- JP
- Japan
- Prior art keywords
- platelet aggregation
- diglucoside
- syringaresinol diglucoside
- syringaresinol
- platelet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- FFDULTAFAQRACT-NYYYOYJKSA-N (-)-syringaresinol O,O'-bis(beta-D-glucoside) Chemical compound COC1=CC([C@H]2[C@H]3[C@H]([C@@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=CC(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FFDULTAFAQRACT-NYYYOYJKSA-N 0.000 claims description 37
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims description 9
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims description 9
- 229940127218 antiplatelet drug Drugs 0.000 claims description 9
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 230000002401 inhibitory effect Effects 0.000 description 17
- 230000000694 effects Effects 0.000 description 12
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 10
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 230000002776 aggregation Effects 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 7
- 210000001772 blood platelet Anatomy 0.000 description 7
- 210000004623 platelet-rich plasma Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000001107 psychogenic effect Effects 0.000 description 4
- 241001632410 Eleutherococcus senticosus Species 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229920001429 chelating resin Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002834 transmittance Methods 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000755716 Convallaria Species 0.000 description 1
- 235000009046 Convallaria majalis Nutrition 0.000 description 1
- 241000218314 Liriodendron tulipifera Species 0.000 description 1
- 241000605411 Lloydia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000012675 alcoholic extract Substances 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- -1 methanol or ethanol Chemical compound 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP812686A JPS62167791A (ja) | 1986-01-20 | 1986-01-20 | 血小板凝集抑制剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP812686A JPS62167791A (ja) | 1986-01-20 | 1986-01-20 | 血小板凝集抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62167791A JPS62167791A (ja) | 1987-07-24 |
| JPH0212932B2 true JPH0212932B2 (US07122603-20061017-C00045.png) | 1990-03-30 |
Family
ID=11684596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP812686A Granted JPS62167791A (ja) | 1986-01-20 | 1986-01-20 | 血小板凝集抑制剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62167791A (US07122603-20061017-C00045.png) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020031563A1 (en) | 1992-09-30 | 2002-03-14 | Hodge Thomas W. | Method of inhibiting tumor necrosis factor |
| KR960037062A (ko) * | 1996-08-02 | 1996-11-19 | 오동덕 | 화농성 피부질환 치료제의 제조방법 |
| KR100481925B1 (ko) * | 2002-01-03 | 2005-04-11 | 정헌택 | 가시오갈피로부터 분리된 아세틸렌 계열 화합물들 및 그를함유하는 아폽토시스 유도제 조성물 |
| BR0312778A (pt) * | 2002-07-18 | 2005-05-03 | Sankyo Co | Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat |
-
1986
- 1986-01-20 JP JP812686A patent/JPS62167791A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS62167791A (ja) | 1987-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI331529B (US07122603-20061017-C00045.png) | ||
| DK172879B1 (da) | Silibininholdigt farmaceutisk præparat | |
| JPS62501360A (ja) | 製薬学的に活性な化合物を含有する病気治療剤 | |
| JPH01157995A (ja) | 鎮痛−抗炎症活性を有するガングリオシドの内部エステル | |
| JPH0212932B2 (US07122603-20061017-C00045.png) | ||
| WO2017113489A1 (zh) | 巨大戟二萜醇类化合物及其在抗hiv潜伏治疗上的应用 | |
| US6475520B1 (en) | Pharmaceutical composition with low toxicity for anti-inflammation and anti-exudation | |
| KR100475647B1 (ko) | 고삼 추출물을 포함하는 성기능 장애 개선용 조성물 | |
| JPH0368516A (ja) | Ｎａ↑＋，Ｋ↑＋‐ＡＴＰａｓｅ阻害剤 | |
| JP2528370B2 (ja) | 抗腫瘍剤 | |
| JPH0717857A (ja) | 循環器疾患治療薬 | |
| JP2541231B2 (ja) | 新規化合物および該化合物を有効成分とする血小板凝集抑制剤 | |
| Jung et al. | Effect of different garlic preparations on the fluidity of blood, fibrinolytic activity, and peripheral microcirculation in comparison with placebo | |
| Carbik et al. | Immunologically active polysaccharides from the aqueous extract of Nerium oleander | |
| CN101856468B (zh) | 一种治疗老年痴呆的药物组合物及其制备方法 | |
| WO2004004708A9 (en) | A pharmaceutical composition useful for treating chronic myeloid leukemia | |
| JPH05246857A (ja) | 痴呆症治療剤 | |
| JPH02243627A (ja) | 狭心症治療薬 | |
| JPH0285211A (ja) | 新規フェネチルアルコール配糖体および免疫抑制剤 | |
| JPS60184017A (ja) | 補気薬 | |
| JPS61277617A (ja) | 坑血小板凝集剤 | |
| JPH02152978A (ja) | 新規リモノイド類および血小板凝集阻害剤 | |
| JPH02243628A (ja) | 血小板凝集阻害剤 | |
| JPH10251154A (ja) | 肝炎抑制組成物 | |
| JPH04187631A (ja) | 過酸化脂質産生抑制剤 |
